However, the phospho-Thr34 DARPP-32 expressing of levodopa liposomes group was significantly lower than the levodopa group, which suggested that application of chitosan-coated levodopa nanoliposomes may reduces the different movement disorder in PD treatment, compared to ordinary levodopa tablets. This evidence concerns the gene PPP1R1B and Parkinson disease.